Advertisement
Advertisement

GERN

GERN logo

Geron Corp

1.27
USD
+0.03
+2.26%
Apr 17, 15:59 UTC -4
Closed
exchange

After-Market

1.27

0.00
+0.16%

Geron Corp Profile

About

Geron is a late-stage clinical biopharmaceutical company focused on the development and potential commercialization of a first-in-class telomerase inhibitor, imetelstat, in hematologic malignancies. The Company currently is conducting two Phase 3 clinical trials: IMerge in lower risk myelodysplastic syndromes and IMpactMF in refractory myelofibrosis.

Info & Links

CEO

JOHN A. SCARLETT

Headquarters

919 EAST HILLSDALE BOULEVARD, SUITE 250
FOSTER CITY, CA 94404, UNITED STATES

Industry

Medical Biomedical And Genetics

Sector

Medical

Website

www.geron.com

Auditor

Ernst & Young LLP

Share holders

439

Employees

229

Geron Corp Statistics

Valuation Measures

Market Capitalization2

808.88M

Enterprise Value

846.48M

Enterprise Value/EBITDA(ttm)

-4.57

Price to Earnings Ratio(ttm)

--

Price to Sales(ttm)

53.93

Price to Book(mrq)

5.42

Price to Cash(ytd)

--

Profitability

Gross Margin(ttm)

98.70%

Operating Margin(ttm)

-682.48%

Profit Margin(ttm)

-6501.77%

Return on Equity(ttm)

-67.53%

Return on Invested Capital(ttm)

-50.23%

Return on Assets(ttm)

-45.46%

Income Statement

Revenue(ttm)

76.99M

Revenue Per Share(ttm)

0.12

Gross Profit(ttm)

75.74M

EBITDA(ttm)3

-185.30M

Net Income Available to Common(ttm)

-174.57M

Diluted EPS(ttm)

-0.32

Share Statistics

Beta (5Y Monthly)

0.53

52-Week Change

-65.54%

S&P 500 52-Week Change

6.35%

S&P 500 Member

Yes

Stock Optionable

Yes

Total Shares Outstanding1

636.90M

Dividend Yield

0.00%

Float4

585.76M

% Held by Insiders

3.10%

% Held by Institutions

73.71%

Balance Sheet

Total Cash(mrq)

408.43M

Total Cash Per Share(mrq)

0.64

Total Debt(mrq)

118.48M

Total Debt/Equity(mrq)

42.26%

Current Ratio(mrq)

5.56%

Quick Ratio(mrq)

2.74%

Book Value Per Share(mrq)

0.46

Cash Flow

Operating Cash Flow Per Share(ytd)

-0.34

Free Cash Flow(ytd)

-219.30M

Table Key

mrq = Most Recent Quarter

ttm = Trailing Twelve Months

ytd = Year To Date

Footnotes

Data provided by Zacks Investment Research or calculated by FXEmpire. All numbers are rounded to the closest decimal.

  • 1 Total Shares outstanding is taken from the most recently filed quarterly or annual report.
  • 2 Market Cap is calculated using total shares outstanding and the most recent share price.
  • 3 EBITDA is calculated using methodology that may differ from that used by a company in its reporting.
  • 4 The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.
Advertisement